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iIn the January 2006 issue of Biology of Blood and
arrow Transplantation, Blum et al [1] reported the out-
omes of 48 patients who underwent unrelated hemato-
oietic transplantation after myeloablative conditioning
t 2 transplant centers over a 12-year period. At a
edian follow-up of 540 days (range, 145-2716 days),
-year survival was superior for those with 5000
eripheral blood blasts/mL at the time of transplan-
ation (18% versus 0%; P  .003) and 20% marrow
lasts (33% versus 5%; P  .04). Sustained survival
ccurred only in patients with low disease burden as
eﬁned previously [1]. Similar results were reported in
4 patients with active disease for matched related
ematopoietic transplantation [2]. Only a few studies
ave addressed the issue of tumor burden at the time
f transplantation [3].
To facilitate patient selection and to deﬁne the
ole of hematopoietic transplantation in patients with
ctive acute myeloid leukemia (AML), we analyzed the
igniﬁcance of residual disease in addition to known
rognostic variables (karyotype, age, performance sta-
us, availability of related donor, and duration of ini-
ial complete remission [CR1]) in 36 patients with
efractory AML between 1982 and 2005 at a single
nstitution [4]. We report the long-term follow-up of
hese patients. After approval by the institutional re-
iew board, patient, disease, and transplant character-
stics were analyzed. Residual bone marrow disease at
ime of transplantation was stratiﬁed into 2 groups
ased on percentage of myeloblasts (group I, 20%
lasts; group II, 20% blasts). Karyotypes were ana-
yzed as good risk versus others [good risk was deﬁned
s t(15;17), inv16, t(16/16), or t(8;21)]. Induction fail-
re, untreated ﬁrst relapse, and refractory ﬁrst or
econd relapse deﬁned disease status.
The median age of 17 female and 19 male subjects
as 35 years (range, 13-62 years). Primary refractory
elapse, refractory relapse, and untreated ﬁrst relapse
ere present in 8 (22.2%), 21 (58.3%), and 7 (19.4%)
atients, respectively. Twenty-four patients (66.7%)
ad 20% blasts and 12 (33.3%) had 20% blasts.
he conditioning regimen consisted of chemotherapy
nd total body irradiation in 23 patients (64%) and
hemotherapy alone in 13 (36%). Graft-versus-host r
B&MTisease (GVHD) prophylaxis consisted of methotrex-
te and cyclosporine or tacrolimus in all 36 patients.
raft characteristics included matched sibling donors
n  21, 58.3%), matched unrelated donors (n  15,
1.7%), bone marrow (n  26, 72.2%), and mobilized
eripheral blood stem cells (n  7, 19.4%). Three pa-
ients (8.3%) received bone marrow and mobilized pe-
ipheral blood stem cells. Cytogenetic information was
vailable in 17 patients (47%); 15 patients (89%) had
ntermediate-risk or poor-risk cytogenetics; good-risk
ytogenetics was present in only 2 patients (11%). Grade
-II and III-IV acute GVHDs occurred in 16 (44.4%)
nd 6 (16.7%) patients, respectively; the overall inci-
ence of grade I-IV acute GVHDs (57.1%) was lower in
atched related transplants than in unrelated donor
ransplants (66.7%). Chronic GVHD (limited  6, ex-
ensive  3) occurred in 9 patients (25%). Of the 21
atients (63.6%) who previously (before transplantation)
chieved remission, median CR1 duration was 6 months
6 months  10, 6-12 months  4, 12 months 
). CR1 information was not available in 3 patients.
lthough 27 patients (75%) achieved CR after trans-
lantation, disease relapse at a median of 3 months
range, 1-52 months) accounted for 54.8% of mortal-
ty. Nonrelapse mortality accounted for 45.2% of
eaths (regimen related toxicity, 19.3%; GVHD and
nfections, 25.9%). Thirty-one patients (86.1%) died
t a median of 4 months (range, 1-52) after transplan-
ation. All 24 patients with 20% marrow blasts (in-
luding 6 with peripheral blasts) died at a median of 3
onths; of the 12 patients with 20% blasts (no
eripheral blast), 7 died at a median of 4 months. Only
patients (13.9%) survived long term at a median
ollow-up of 30 months (range, 13-64 months). All
urvivors had 20% residual marrow blasts, no pe-
ipheral blast, and intermediate risk cytogenetics. No
ther variable such as age, performance status, donor
ype, or duration of CR1 correlated with survival.
A higher relapse rate in patients with AML who
resent with excess myeloblasts at transplantation
ikely reﬂects a unique subgroup with intrinsic resis-
ance to treatment. Although CR rates after allograft-
ng for residual AML is high (75%), higher relapse
ates of approximately 50-60% and 40-40% for non-
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6elapse mortality result in a dismal 10% in long-term
urvivors. This observation is important to bear in
ind while counseling patients with refractory relapse
or allogeneic transplantation or clinical trials.
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